| Primary information |
|---|
| sequence ID | Seq_7645 |
| Peptide sequence | SSKITHRIHWESASL |
| CancerPDF_ID | CancerPDF_ID33, CancerPDF_ID1049, |
| PMID | 16896061,16395409 |
| Protein Name | Complement C3f,Complement C3f |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN |
| Fluid | Serum,Serum |
| M/Z | 1751.88,1751.88 |
| Charge | 1,1 |
| Mass (in Da) | 1751.91,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,less than 1 “5 |
| CancerPDF_ID | CancerPDF_ID33, CancerPDF_ID1049, |
| p-Value | 1.00E-05,9.48E-13 |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows) |
| Length | 15,15 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer" |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database |
| Modification | NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy" |
| Regulation | NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.82, 5.7 and 1.36 in prostate, bladder and breast cancer respectively" |
| Validation | Independent validation,Independent validation |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset |
| Specificity | 95% on independent dataset,NA |
| Accuracy | NA,97.5 % on validation dataset |
| Peptide Atlas | NA |
| IEDB | 533899
|